STUB1/CYLD targets VDAC1 to regulate osteogenic differentiation in osteoporosis via modulating its ubiquitination and oligomerization
Biochemical Pharmacology · 2026-12 · 254 · 118583
DOI: 10.1016/j.bcp.2026.118583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-12. Verfasst von Shan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Dalian Medical University, 9 West Section, Lvshun South Road, Lvshunkou District, Dalian 116044, China. Hauptthemen laut MEDLINE: Voltage-Dependent Anion Channel 1, Osteogenesis, Ubiquitin-Protein Ligases, Cell Differentiation. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Osteoporosis (OP) constitutes a major global public health burden whose progression is closely linked to mitochondrial dysfunction and disrupted mitophagy homeostasis. This study was designed to characterize the critical function of voltage-dependent anion-selective channel protein 1 (VDAC1), an outer mitochondrial membrane channel protein, in OP and clarify the underlying mechanisms of VDAC1 modulating osteoblastic differentiation of BMSCs via its own ubiquitination and oligomerization under the action of STUB1/CYLD. Bioinformatic analysis of postmenopausal osteoporosis dataset GSE230665 identified VDAC1 as a core node linking mitophagy and osteoporosis. In vivo, AAV9-VDAC1 overexpression vector (AAV9-OE-VDAC1) alleviated osteoporotic phenotypes in ovariectomized (OVX) mice. In vitro, VDAC1 overexpression restored mitophagy and facilitated osteogenic differentiation of hydrogen peroxide (H2O2) -damaged bone marrow mesenchymal stem cells (BMSCs). VDAC1's stability is finely tuned by post-translational ubiquitination: STIP1 homology and U-box containing protein 1 (STUB1), an E3 ubiquitin ligase, triggers VDAC1 degradation through K48- and K63-linked ubiquitination, whereas cylindromatosis tumor suppressor (CYLD), a deubiquitinase, stabilizes VDAC1 by removing K63 ubiquitin chains. Oxidative stress induces aberrant VDAC1 oligomerization to suppress mitophagy and osteogenesis, which is rescued by oligomer inhibitor VBIT-4. Upregulated ubiquitination of VDAC1 aggravates its pathological oligomerization, forming a mutually reinforcing vicious cycle. Pharmacological inhibition of these two modifications could delay osteoporosis progression under experimental conditions. Collectively, targeting the STUB1/CYLD-VDAC1 axis to restore mitophagy and rescue impaired osteogenic differentiation of BMSCs may provide a potential research perspective for developing therapeutic strategies against OP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Dalian Medical University, 9 West Section, Lvshun South Road, Lvshunkou District, Dalian 116044, China.
- The First Affiliated Hospital, Dalian Medical University, No. 222, Zhongshan Road, Xigang District, Dalian 116011, China.
- College of Pharmacy, Dalian Medical University, 9 West Section, Lvshun South Road, Lvshunkou District, Dalian 116044, China. Electronic address: sunhuijun@dmu.edu.cn.
- The First Affiliated Hospital, Dalian Medical University, No. 222, Zhongshan Road, Xigang District, Dalian 116011, China. Electronic address: mozhenliu@dmu.edu.cn.
Zitieren
APA
Wang, S., Fan, S., Sang, W., Sun, Y., Wang, C., Lu, K., Sun, H., & Liu, M. (2026). STUB1/CYLD targets VDAC1 to regulate osteogenic differentiation in osteoporosis via modulating its ubiquitination and oligomerization. Biochemical Pharmacology, 254, 118583. https://doi.org/10.1016/j.bcp.2026.118583
Vancouver
Wang S, Fan S, Sang W, Sun Y, Wang C, Lu K, et al. STUB1/CYLD targets VDAC1 to regulate osteogenic differentiation in osteoporosis via modulating its ubiquitination and oligomerization. Biochemical Pharmacology. 2026;254:118583. doi:10.1016/j.bcp.2026.118583
BibTeX
@article{Wang2026,
author = {Wang, Shan and Fan, Sihang and Sang, Wanyu and Sun, Yi and Wang, Changyuan and Lu, Kangjun and Sun, Huijun and Liu, Mozhen},
title = {STUB1/CYLD targets VDAC1 to regulate osteogenic differentiation in osteoporosis via modulating its ubiquitination and oligomerization},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {254},
pages = {118583},
doi = {10.1016/j.bcp.2026.118583}
}
EUVIMED